Lipocine vs Scienture Holdings
Lipocine is the larger business, with $2.0m of revenue in fiscal 2025 against $431,609 for Scienture Holdings (4.6 times as much). Scienture Holdings grew faster (215.9% against -82.3%). Lipocine kept more of each dollar of sales as profit: a net margin of -487.1% against -9618.0%. Lipocine carries less debt relative to equity (0.0% against 2.9%).
| Latest fiscal year | LipocineLPCN, 2025 | Scienture HoldingsSCNX, 2025 |
|---|---|---|
| Revenue | $2.0m | $431,609 |
| Revenue growth | -82.3% | 215.9% |
| Net income | −$9.6m | −$41.5m |
| Operating margin | -524.7% | -9867.9% |
| Net margin | -487.1% | -9618.0% |
| Return on equity | -54.3% | -55.6% |
| Free cash flow | −$9.8m | −$13.4m |
| Cash | $5.2m | $6.7m |
| Total debt | $0 | $2.0m |
| Debt to equity | 0.0% | 2.9% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 14 | — |
| Market value | $12.0m | $134m |
| Price vs our value range | — | — |
| Moat score | 12 (Weak) | 29 (Weak) |
| Insider trades, 12 months | 7 buys, 0 sales | 0 buys, 0 sales |